ANGIO-CONRAY
LOE Approachingiothalamate sodium
NDAINJECTIONINJECTABLE
Approved
Apr 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ANGIO-CONRAY (iothalamate sodium) is clinical pharmacology the renal clearance of sodium iothalamate in man closely approximates that of inulin. First approved in 1996.
Drug data last refreshed 4m ago · AI intelligence enriched 4m ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANGIO-CONRAY (sodium iothalamate) is a radioiodine-labeled contrast agent administered by injection for diagnostic imaging purposes. It works through glomerular filtration without tubular reabsorption or secretion, making it useful for renal function assessment and imaging studies. The drug's mechanism closely mirrors inulin clearance, providing accurate measurement of kidney filtration capacity.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure (30/100); expect declining team investment and transition focus toward lifecycle management.
Mechanism of Action
CLINICAL PHARMACOLOGY The renal clearance of sodium iothalamate in man closely approximates that of inulin. The compound is cleared by glomerular filtration without tubular secretion or reabsorption. Following infusion administration of I-125 iothalamate, the effective half-life is about 0.07 days.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ANGIO-CONRAY offers limited career growth given the LOE-approaching lifecycle and zero linked job openings. Career professionals should expect focus on operational efficiency, regulatory compliance, and managed decline strategies rather than expansion or innovation.
Product Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.